

# Giannicola Genovese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7847629/publications.pdf>

Version: 2024-02-01

47  
papers

11,467  
citations

159358

30  
h-index

197535

49  
g-index

54  
all docs

54  
docs citations

54  
times ranked

22508  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2013, 155, 462-477.	13.5	3,979
2	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	13.5	2,562
3	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. <i>Nature</i> , 2014, 514, 628-632.	13.7	998
4	Emerging insights into the molecular and cellular basis of glioblastoma. <i>Genes and Development</i> , 2012, 26, 756-784.	2.7	463
5	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	2.9	416
6	Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. <i>Nature Medicine</i> , 2012, 18, 1503-1510.	15.2	333
7	Passenger deletions generate therapeutic vulnerabilities in cancer. <i>Nature</i> , 2012, 488, 337-342.	13.7	294
8	Post-translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair. <i>Cell Reports</i> , 2016, 14, 1555-1566.	2.9	237
9	Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. <i>Nature</i> , 2017, 542, 119-123.	13.7	209
10	The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF. <i>Cancer Research</i> , 2014, 74, 4845-4852.	0.4	148
11	Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. <i>Cancer Discovery</i> , 2020, 10, 608-625.	7.7	119
12	InÂVivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. <i>Cell Reports</i> , 2016, 16, 133-147.	2.9	114
13	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. <i>Nature</i> , 2017, 542, 362-366.	13.7	105
14	microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-Î² Signaling in Glioblastoma. <i>Cancer Discovery</i> , 2012, 2, 736-749.	7.7	99
15	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. <i>Science</i> , 2021, 373, eabj0486.	6.0	99
16	Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. <i>Cancer Cell</i> , 2015, 27, 644-657.	7.7	85
17	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	5.8	84
18	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. <i>Cancer Cell</i> , 2020, 37, 720-734.e13.	7.7	74

#	ARTICLE	IF	CITATIONS
19	Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. <i>Cell Reports</i> , 2019, 26, 1518-1532.e9.	2.9	70
20	Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 659-668.	0.6	70
21	Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 1091-1101.	0.4	68
22	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 35, 204-220.e9.	7.7	62
23	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 1-6.	0.9	60
24	Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 71.	3.5	51
25	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2014, 157, 753.	13.5	51
26	The tumor suppressor HINT1 regulates MITF and $\beta$ -catenin transcriptional activity in melanoma cells. <i>Cell Cycle</i> , 2012, 11, 2206-2215.	1.3	44
27	Actein inhibits the Na <sup>+</sup> -K <sup>+</sup> -ATPase and enhances the growth inhibitory effect of digitoxin on human breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 375, 608-613.	1.0	39
28	Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: Implications for its detection. <i>Journal of Cellular Physiology</i> , 2010, 224, 234-241.	2.0	36
29	Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 103-116.	0.9	31
30	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2021, 12, 4626.	5.8	31
31	Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma. <i>Cancer Biology and Therapy</i> , 2007, 6, 1840-1846.	1.5	30
32	Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100166.	0.7	23
33	Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. <i>Cancer Discovery</i> , 2021, 11, 2904-2923.	7.7	23
34	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. <i>Gastroenterology</i> , 2021, 161, 196-210.	0.6	23
35	Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. <i>Cancer Research</i> , 2021, 81, 332-343.	0.4	22
36	Loss of nuclear p27 <sup>kip1</sup> and $\beta$ -dystroglycan is a frequent event and is a strong predictor of poor outcome in renal cell carcinoma. <i>Cancer Science</i> , 2010, 101, 2080-2086.	1.7	21

#	ARTICLE	IF	CITATIONS
37	Identification of Sp1 and GC-boxes as transcriptional regulators of mouse <i>Dag1</i> gene promoter. American Journal of Physiology - Cell Physiology, 2009, 297, C1113-C1123.	2.1	20
38	TAM kinase inhibition and immune checkpoint blockade “ a winning combination in cancer treatment?. Expert Opinion on Therapeutic Targets, 2021, 25, 141-151.	1.5	17
39	Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers, 2021, 13, 2170.	1.7	15
40	Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?. Oncotarget, 2019, 10, 3979-3981.	0.8	15
41	Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clinical Genitourinary Cancer, 2021, 19, e401-e408.	0.9	14
42	Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers, 2021, 13, 6022.	1.7	14
43	Leukotrienes, a potential target for Covid-19. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 161, 102174.	1.0	12
44	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. European Urology Oncology, 2023, 6, 228-232.	2.6	11
45	Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye. Molecular and Cellular Oncology, 2020, 7, 1777060.	0.3	10
46	Multi-site desmoplastic small round cell tumors are genetically related and immune-cold. Npj Precision Oncology, 2022, 6, 21.	2.3	7
47	Cancer Genetics and Therapeutic Opportunities in Urologic Practice. Cancers, 2020, 12, 710.	1.7	3